FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891534801> ?p ?o ?g. }

• W2891534801 endingPage "e1138" @default.
• W2891534801 startingPage "e1132" @default.
• W2891534801 abstract "BackgroundMass drug administration has made a major contribution to the public health control of several important neglected tropical diseases. For settings with more than one endemic disease, combined mass drug administration has potential practical advantages compared with separate programmes but needs confirmation of feasibility and safety. We undertook a study of mass drug administration in the Solomon Islands for trachoma and scabies control using ivermectin and azithromycin, key drugs in the control of neglected tropical diseases worldwide.MethodsThe entire population of Choiseul province, Solomon Islands, was eligible to participate. An azithromycin-based mass drug administration regimen was offered in line with standard recommendations for trachoma elimination (oral azithromycin or topical tetracycline). An ivermectin-based mass drug administration regimen was offered at the same time (oral ivermectin or topical permethrin), with a further dose 7–14 days later, using a modified version of a regimen demonstrated to be effective for scabies control. All participants underwent safety assessments 7–14 days later. Participants in ten randomly selected sentinel villages underwent a more detailed safety assessment. Routine health system reports of hospital or clinic admissions and deaths were also obtained to compare health outcomes in the 12 month period before and after the mass drug administration.FindingsThe study enrolled 26 188 participants, 99·3% of the estimated resident population as determined at the 2009 census. Of those enrolled, 25 717 (98·2%) received the trachoma regimen and 25 819 (98·6%) received the first dose of the scabies regimen between Sept 1, and Oct 2, 2015. A second dose of the scabies regimen was received by 21 931 (83·7%) of participants. Adverse events, all mild and transient, were recorded in 571 (2·6%) of the entire study population and 58 (4·1%) of participants in the ten sentinel villages. In the 12 months before and after the mass drug administration the numbers of hospital admissions (1530 vs 1602) and deaths (73 vs 83) were similar. In the month after the mass drug administration, 84 individuals were admitted to hospital and two died, compared with a monthly median of 116 admissions (IQR 106–159) and six deaths (IQR 4–7) in the 12 months before and after the mass drug administration.InterpretationIn the largest trial so far involving coadministration of regimens based on ivermectin and azithromycin, the combination was safe and feasible in a population of more than 26 000 people. Coadministration of mass drug administration based on these two drugs opens up new potential for the control of neglected tropical diseases.FundingInternational Trachoma Initiative, Murdoch Children's Research Institute, Scobie and Claire Mackinnon Trust, Wellcome Trust." @default.
• W2891534801 created "2018-09-27" @default.
• W2891534801 creator A5014601247 @default.
• W2891534801 creator A5025372817 @default.
• W2891534801 creator A5049028027 @default.
• W2891534801 creator A5051627874 @default.
• W2891534801 creator A5055059882 @default.
• W2891534801 creator A5069014035 @default.
• W2891534801 creator A5069222004 @default.
• W2891534801 creator A5070811297 @default.
• W2891534801 creator A5073636405 @default.
• W2891534801 creator A5079591035 @default.
• W2891534801 creator A5083908248 @default.
• W2891534801 date "2018-10-01" @default.
• W2891534801 modified "2023-10-16" @default.
• W2891534801 title "Feasibility and safety of mass drug coadministration with azithromycin and ivermectin for the control of neglected tropical diseases: a single-arm intervention trial" @default.
• W2891534801 cites W145658952 @default.
• W2891534801 cites W1559229543 @default.
• W2891534801 cites W1837411754 @default.
• W2891534801 cites W1961648385 @default.
• W2891534801 cites W1969364229 @default.
• W2891534801 cites W1974260500 @default.
• W2891534801 cites W1981367337 @default.
• W2891534801 cites W1985493133 @default.
• W2891534801 cites W2000402496 @default.
• W2891534801 cites W2047284400 @default.
• W2891534801 cites W2054748362 @default.
• W2891534801 cites W2072921654 @default.
• W2891534801 cites W2081438866 @default.
• W2891534801 cites W2089694174 @default.
• W2891534801 cites W2089953642 @default.
• W2891534801 cites W2098013497 @default.
• W2891534801 cites W2101264978 @default.
• W2891534801 cites W2104543391 @default.
• W2891534801 cites W2135242235 @default.
• W2891534801 cites W2153972688 @default.
• W2891534801 cites W2158832254 @default.
• W2891534801 cites W2162950025 @default.
• W2891534801 cites W2204877269 @default.
• W2891534801 cites W2302211553 @default.
• W2891534801 cites W2317702186 @default.
• W2891534801 cites W2460458040 @default.
• W2891534801 cites W2500390374 @default.
• W2891534801 cites W2518883321 @default.
• W2891534801 cites W2520017917 @default.
• W2891534801 cites W2566682838 @default.
• W2891534801 cites W4211108838 @default.
• W2891534801 doi "https://doi.org/10.1016/s2214-109x(18)30397-8" @default.
• W2891534801 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6139784" @default.
• W2891534801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30223985" @default.
• W2891534801 hasPublicationYear "2018" @default.
• W2891534801 type Work @default.
• W2891534801 sameAs 2891534801 @default.
• W2891534801 citedByCount "27" @default.
• W2891534801 countsByYear W28915348012018 @default.
• W2891534801 countsByYear W28915348012019 @default.
• W2891534801 countsByYear W28915348012020 @default.
• W2891534801 countsByYear W28915348012021 @default.
• W2891534801 countsByYear W28915348012022 @default.
• W2891534801 countsByYear W28915348012023 @default.
• W2891534801 crossrefType "journal-article" @default.
• W2891534801 hasAuthorship W2891534801A5014601247 @default.
• W2891534801 hasAuthorship W2891534801A5025372817 @default.
• W2891534801 hasAuthorship W2891534801A5049028027 @default.
• W2891534801 hasAuthorship W2891534801A5051627874 @default.
• W2891534801 hasAuthorship W2891534801A5055059882 @default.
• W2891534801 hasAuthorship W2891534801A5069014035 @default.
• W2891534801 hasAuthorship W2891534801A5069222004 @default.
• W2891534801 hasAuthorship W2891534801A5070811297 @default.
• W2891534801 hasAuthorship W2891534801A5073636405 @default.
• W2891534801 hasAuthorship W2891534801A5079591035 @default.
• W2891534801 hasAuthorship W2891534801A5083908248 @default.
• W2891534801 hasBestOaLocation W28915348011 @default.
• W2891534801 hasConcept C126322002 @default.
• W2891534801 hasConcept C141071460 @default.
• W2891534801 hasConcept C142724271 @default.
• W2891534801 hasConcept C2776246342 @default.
• W2891534801 hasConcept C2777034029 @default.
• W2891534801 hasConcept C2777499811 @default.
• W2891534801 hasConcept C2778907293 @default.
• W2891534801 hasConcept C2779134260 @default.
• W2891534801 hasConcept C2780133432 @default.
• W2891534801 hasConcept C2781413609 @default.
• W2891534801 hasConcept C2908647359 @default.
• W2891534801 hasConcept C42972112 @default.
• W2891534801 hasConcept C501593827 @default.
• W2891534801 hasConcept C71924100 @default.
• W2891534801 hasConcept C86803240 @default.
• W2891534801 hasConcept C89423630 @default.
• W2891534801 hasConcept C99454951 @default.
• W2891534801 hasConceptScore W2891534801C126322002 @default.
• W2891534801 hasConceptScore W2891534801C141071460 @default.
• W2891534801 hasConceptScore W2891534801C142724271 @default.
• W2891534801 hasConceptScore W2891534801C2776246342 @default.
• W2891534801 hasConceptScore W2891534801C2777034029 @default.
• W2891534801 hasConceptScore W2891534801C2777499811 @default.
• W2891534801 hasConceptScore W2891534801C2778907293 @default.
• W2891534801 hasConceptScore W2891534801C2779134260 @default.

• next